Special Issue "Generic Drugs"


A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (30 April 2010)

Special Issue Editor

Guest Editor
Andrew Nathan Wilner, MD
111 Durfee Street, P.O. Box 831, Fall River, MA 02722, USA
Website: http://www.drwilner.org/
E-Mail: andrew@drwilner.org

Special Issue Information

Dear Colleagues,

The pressure to contain health care costs has propelled the prescribing of generic drugs and the practice of generic substitution. For people with epilepsy, for example, the switch from brand to generic, generic to generic, or generic to brand may come with the risks of adverse events and breakthrough seizures, although the magnitude of these risks and the vulnerable populations remain undefined. Frequent anecdotal reports from patients and physicians are echoed in survey data regarding the lack of bioeffectiveness of generic epilepsy drugs, despite FDA mandated “bioequivalence.” Claims data suggest that epilepsy patients who take generic drugs have an increased use of health care resources such as emergency room visits, hospitalizations, and other medications, challenging the argument that generic drugs are “cost effective.” The purpose of this special issue is to assess the current status of generic drugs with respect to effectiveness, tolerability, safety, and quality of life in the treatment of epilepsy and other diseases, and to help guide policy development and physicians in the care of their patients.

Dr. Andrew Nathan Wilner
Guest Editor


  • adverse events
  • antiepileptic drugs
  • bioequivalence
  • brand
  • substitution
  • breakthrough seizures
  • cost effective
  • epilepsy
  • generic drugs
  • generic substitution
  • therapeutic range

Published Papers (2 papers)

by , , , , , , , , , , , , , , ,  and
Pharmaceuticals 2010, 3(8), 2470-2494; doi:10.3390/ph3082470
Received: 1 July 2010; in revised form: 27 July 2010 / Accepted: 4 August 2010 / Published: 5 August 2010
Show/Hide Abstract | Cited by 29 | PDF Full-text (215 KB) | HTML Full-text | XML Full-text

by  and
Pharmaceuticals 2010, 3(3), 471-481; doi:10.3390/ph3030471
Received: 8 December 2009; in revised form: 11 February 2010 / Accepted: 3 March 2010 / Published: 5 March 2010
Show/Hide Abstract | Cited by 9 | PDF Full-text (203 KB) | HTML Full-text | XML Full-text

Last update: 4 March 2014

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert